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 II 
Abstract 
 
 
Cobalt-chromium (CoCr) alloys are widely used as biomaterials for coronary stents 
due to their excellent mechanical properties, biocompatibility and corrosion 
resistance. However, these materials are bioinert, retarding the complete 
endothelialization and resulting in a higher risk of restenosis, narrowing of the 
artery, and late-stent thrombosis. Therefore, the improvement of implants surface 
endothelialization has acquired importance in the last years.  
 
Immobilization of cell adhesive biomolecules onto biomaterials surface is a well-
known strategy to control cell response. However, the strategy of immobilization, 
the optimal combination or the appropriate spatial presentation of the bioactive 
sequences to enhance endothelialization for cardiovascular applications, remains 
to be elucidated.  
 
The present PhD thesis focused on the development of a new biofunctionalized 
CoCr alloy surfaces in order to improve the endothelialization. To that end, elastin-
like recombinamers (ELR) genetically modified with an REDV (Arg-Glu-Asp-Val) 
sequence and short synthetized peptides RGDS (Arg-Gly-Asp-Ser), REDV, YIGSR 
(Tyr-Ile-Gly-Ser-Arg) and their equimolar combination, were attached by 
physisorption and covalent bonding onto CoCr alloy surfaces and thoroughly 
characterized physico-chemically and evaluated in vitro with human umbilical vein 
endothelial cells (HUVECs), coronary artery smooth muscle cells (CASMCs) and 
platelets from blood donors.  
 
First, biofunctionalized surfaces with ELR were developed and optimized by 
evaluating different surface activation treatments, oxygen plasma and sodium 
hydroxide etching, and different binding strategies, physisorption and covalent 
bonding. The functionalized surfaces demonstrated a higher cell adhesion and 
spreading of HUVEC cells, this effect is emphasized as increases the amount of 
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immobilized biomolecules and directly related to the immobilization technique: 
covalent bonding. Nevertheless, the silanization process was not completely 
effective since a mixture of covalent and physisorption behavior was observed 
probably due to the use of big molecules that decreased the control of the 
bonding between the biomolecule and the surface.  
Secondly, it was synthetized immobilized RGDS, REDV, YIGSR and their equimolar 
combination peptides onto the different surfaces. Cell studies demonstrated that 
the covalent functionalization of CoCr surfaces with an equimolar combination of 
RGDS/YIGSR represented the most powerful strategy to enhance the early stages 
of HUVECs adhesion, proliferation and migration, indicating a positive synergistic 
effect between the two peptide motifs. Besides, gene expression and platelet 
adhesion studies showed that surfaces silanized with the combination 
RGDS/YIGSR improved anti-thrombogenicity compared to non-modified surfaces.  
 
Finally, cell co-cultures of HUVECs/CASMCs found that functionalization 
increased the amount of adhered HUVECs onto modified surfaces compared to 
plain CoCr, independently of the used peptide and the strategy of immobilization. 
Overall, the present thesis offer a comprehensive view of the effectiveness of 
immobilizing cell adhesive molecules onto CoCr alloy surfaces to enhance 
endothelialization while preventing restenosis and thrombosis for cardiovascular 
applications.  
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Resumen 
 
 
Las aleaciones de cobalto-cromo (CoCr) son ampliamente utilizadas como 
biomateriales para stents coronarios debido a sus excelentes propiedades 
mecánicas, biocompatibilidad y resistencia a la corrosión. Sin embargo, estos 
materiales son bio-inertales, retardando la completa endotelialización y resultando 
en un mayor riesgo de reestenosis, estrechamiento de la arteria y trombosis tardía. 
Por lo tanto, la mejora de la endotelización de superficie de los implantes ha 
adquirido importancia en los últimos años. 
 
La inmovilización de biomoléculas adhesivas celulares sobre la superficie de los 
biomateriales es una estrategia bien conocida para controlar la respuesta celular. 
Sin embargo, queda por aclararse la estrategia de inmovilización, la combinación 
óptima o la presentación espacial apropiada de las secuencias bioactivas para 
potenciar la endotelización en aplicaciones cardiovasculares. 
 
La presente tesis doctoral se centró en el desarrollo de una nueva superficie 
biofuncionalizada de la aleación CoCr con el fin de mejorar la endotelialización. 
Para ello, los recombinameros tipo elastina (ELR) modificados genéticamente con 
una secuencia REDV (Arg-Glu-Asp-Val) y péptidos cortos sintetizados RGDS (Arg-
Gly-Asp-Ser), REDV, YIGSR (Tyr-Ile-Gly -Ser-Arg) y su combinación equimolar, 
fueron anclados por fisisorción y unión covalente a las superficies de la aleación, 
se caracterizaron físicamente-químicamente y evaluó in vitro con células 
endoteliales de vena umbilical humana (HUVECs), células de músculo liso de 
arteria coronaria (CASMCs) y plaquetas de donantes de sangre. 
 
En primer lugar, se desarrollaron y optimizaron las superficies biofuncionalizadas 
con ELR mediante la evaluación de diferentes tratamientos de activación 
superficial: plasma de oxígeno y ataque con hidróxido de sodio, y diferentes 
estrategias de unión: fisisorción y unión covalente. Las superficies funcionalizadas 
demostraron una mayor adhesión celular y propagación de células HUVEC, este 
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efecto se enfatiza a medida que aumenta la cantidad de biomoléculas 
inmovilizadas y se relaciona directamente con la técnica de inmovilización: la unión 
covalente. Sin embargo, el proceso de silanización no fue completamente efectivo, 
ya que se observó una mezcla de uniones covalentes y fisisorbidas, probablemente 
debido al uso de grandes moléculas que disminuyeron el control de la unión entre 
la biomolécula y la superficie. 
En segundo lugar, se inmovilizado los péptidos sintetizados RGDS, REDV, YIGSR y 
sus combinaciones equimolares sobre las diferentes superficies. Los estudios 
celulares demostraron que la funcionalización covalente de las superficies de CoCr 
con una combinación equimolar de RGDS/YIGSR representó la estrategia más 
potente para potenciar las etapas tempranas de la adhesión, proliferación y 
migración de HUVECs, indicando un efecto sinérgico positivo entre los dos 
motivos peptídicos. Además, la expresión génica y los estudios de adhesión 
plaquetaria mostraron que las superficies silanizadas con la combinación 
RGDS/YIGSR mejoraron la antitrombogenicidad en comparación con las 
superficies no modificadas. 
 
Finalmente, con los co-cultivos celulares de HUVECs/CASMCs se encontró que la 
funcionalización aumentaba la cantidad de HUVEC adheridas sobre las superficies 
modificadas en comparación con CoCr simple, independientemente del péptido 
usado y la estrategia de inmovilización. 
En general, la presente tesis ofrece una visión completa de la efectividad de la 
inmovilización de moléculas adhesivas celulares en la superficie de la aleación 
CoCr para mejorar la endotelialización, mientras que previene la reestenosis y 
trombosis en aplicaciones cardiovasculares. 
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General Objectives 
 
 
In-stent restenosis, stents thrombosis and incomplete stent endothelialization 
remain the principal mechanisms for the failure of the bare metal stents (BMS). In 
the present PhD thesis, new functionalized CoCr surfaces have been developed to 
modulate ECs response, in order to reduce BMS failure caused by a poor 
endothelialization.  
 
The main specific objectives of this thesis are summarized as follows:  
(i) To develop new surface biochemical coatings onto CoCr alloy in order to 
enhance endothelialization with the use of elastin-like recombinamers (ELR) 
(Chapter 3) and short synthetic peptides (Chapter 4 and 5).  
• Immobilization of an Elastin-like recombinamer with an Arg-Glu-Asp-Val 
(REDV) bioactive sequence coating by physisorption and covalent binding 
with CPTES silane. (Chapter 3)  
• Design and synthesis of short peptides with the following cell adhesive 
biomolecules: Arg- Gly – Asp - Ser (RGDS), Arg-Glu-Asp-Val (REDV) and 
Tyr-Ile-Gly-Ser-Arg (YIGSR) peptides (Chapter 4).  
• Optimization of the immobilization process of RGDS, REDV, YIGSR and 
their equimolar combination by physisorption and silanization with CPTES. 
(Chapter 4)  
 
(ii) To evaluate the biofunctionalized surfaces in vitro with endothelial cells (ECs), 
smooth muscle cells (SMCs) and platelets (Chapter 3, 4, 5).  
• Endothelialization properties of functionalized surfaces by the analysis of 
ECs adhesion onto ELR REDV coated surfaces (Chapter 3) and ECs 
adhesion, proliferation and migration onto short peptides coated surfaces 
(Chapter 4);  
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• Restenosis properties of short peptide functionalized surfaces by the 
analysis of SMCs adhesion (Chapter 4) and cell co-culture ECs/SMCs 
studies (Chapter 5) 
• Thrombogenicity properties of short peptide functionalized surfaces by the 
analysis of the expression of pro-thrombogenic and anti-thrombogenic 
genes. and in vitro platelets adhesion and aggregation (Chapter 5)   
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1 Chapter 1: Introduction  
 
 
 
Cardiovascular disease, specifically coronary disease, remains the first cause of 
death among Europeans and around the world [1]. Coronary angioplasty with the 
insertion of a stent,  also known as percutaneous coronary intervention (PCI), is 
the major surgery to solve atherosclerosis [2,3]. Atherosclerosis, which is the 
build-up of fatty material inside of your arteries forming a plaque,  causes 
narrowing of the vessel wall [4]. The insertion of a bare metal stent (BMS) isn't 
risk-free. Neointimal hyperplasia refers to proliferation and migration of vascular 
SMCs and in-stent restenosis (ISR) has been a relatively common complication 
associated with bare metal stents (BMS). [5,6]. Also, thrombosis is a common 
drawback where a blood clot can form and cause your arteries to narrow again 
suddenly and it may even cause a complete blockage.  
 
Thrombosis and ISR are the main obstacles for the healing process of the artery 
and endothelium recovery, after cardiovascular surgery of BMS. A promising way 
to achieve the healing of the endothelium after Percutaneous coronary 
intervention (PCI) may rely on fostering a rapid in situ endothelialization onto the 
implant surface by applying biochemical surface modifications.  
 
CoCr alloys (i.e. ASTM F90) have been widely used as biomaterials since it does 
not evoke an inflammatory reaction when implanted. Moreover, they are widely 
used for stent manufacturing since they have exhibited a high strength and 
hardness, providing support to the retracting force created by diseased artery. As 
well as a high resistance to corrosion and wear due to the natural and 
spontaneous generation of a layer of chromium oxide that appears on the surface 
[7]. Nevertheless, the CoCr alloys surfaces are inert and do not promote any cell 
behavior.  
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Several studies have demonstrated that any surface treatment that fosters stent 
surface endothelialization will help to inhibit restenosis and thrombosis [8–10]. 
Different strategies have been developed onto BMS in order to overcome the 
mentioned problems. Passive coatings include inorganic and organic coatings with 
the aim to act as an inert barrier between the blood flow /tissue and the metal [6]. 
Also, micro- and nano-topographies, independent of surface chemistry, have 
shown to influences endothelialization [11]. Finally, biochemical surface 
modification with the immobilization of biomolecules, will activate the biomaterial 
surface and induce specific cell and tissue response. Biofunctionalization of CoCr 
surfaces with the immobilization of biopolymers or cell adhesive motifs derived 
from the extracellular matrix (ECM) [12,13], is a powerful approach to stimulate 
cell response and accelerate the biomaterials integration. 
 
The overall aim of this thesis was to develop a new family of biofunctionalized 
CoCr alloy surfaces by covalently-anchoring cell adhesive motifs to modulate 
endothelial cells response, in order to prevent atherosclerosis, ISR and thrombosis 
diseases. Different strategies have been studied in order to enhance 
endothelialization such as elastin-like-biopolymers and cell adhesive motifs (i.e. 
peptides RGDS, REDV and YIGSR) (Paper I (Chapter 3), Paper II (Chapter 4) and 
Paper III (Chapter 5)). 
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1.1 Paper I (Chapter 3)  
Biofunctionalization of REDV elastin-like recombinamers improves 
endothelialization on CoCr alloy surfaces for cardiovascular applications  
Authors: Castellanos MI, Zenses AS, Grau A, Rodriguez-Cabello JC, Gil FJ, Manero 
JM, Pegueroles M. 
Manuscript published; Colloids and Surfaces B: Biointerfaces 2015; 127, 22-32. 
(DOI: 10.1016/j.colsurfb.2014.12.056) 
IF: 3.902, Q1, ranked 8/33 in the category ¨ Material Science, Biomaterials¨.   
Presented in 3erd TERMIS World Congress, Vienna, Austria. September 2012 and 
XXXV SIBB Congress, Madrid, Spain, October 2012.  
Author's contribution: Major part of planning and analysis. Performed all the 
experiments, the analysis of the study and wrote the paper.  
 
The manuscript is the result of the development and characterization of a new 
family of functionalized CoCr surfaces. For that, surfaces were activated with 
oxygen plasma and sodium hydroxide, previous to silanization and finally, an 
elastin-like recombinant protein genetically modified with the REDV sequence was 
immobilized. This motif is a bioactive specific domain for ECs attachment.  
 
The main purpose of this study was the analysis and comparison between the 
immobilization of the ELR through physical adsorption and covalent bonding 
through the analysis of the amount of the biomolecule binded onto the material 
and the ECs in vitro response. This is the first time that ELR with REDV sequence 
has been immobilized onto CoCr surfaces with the objective to ameliorate 
endothelialization.  
The REDV ELR was successfully immobilized onto CoCr surfaces and promotes 
ECs adhesion and spreading. This effect is emphasized as increases the amount of 
immobilized biomolecules. This study allowed to optimize the biofunctionalization 
process onto CoCr surfaces and demonstrated that biofunctionalization is a well-
established process to control and guide cellular response onto biomaterials.  
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1.2 Paper II (Chapter 4)  
Functionalization of CoCr surfaces with cell adhesive peptides to promote 
HUVECs adhesion and proliferation  
Authors: Castellanos MI, Mas-Moruno C, Grau A, Serra-Picamal X, Trepat X, 
Albericio F, Joner M, Gil FJ, Ginebra MP, Manero JM, Pegueroles M. 
Manuscript published; Applied Surface Science 2017; 393, 82-92. 
(DOI: 10.1016/j.apsusc.2016.09.107) 
IF: 3.150 (2015), Q1, ranked 14/25 in the category ¨Material Science, Surfaces, 
Coating and Films¨ 
Presented in 6th EEIGM International Conference, Nancy, France. November 
2011.  
Author's contribution: Major part of planning and analysis. Performed all the 
experiments, the analysis of the study and wrote the paper. 
 
The manuscript describes the development and characterization of functionalized 
CoCr surfaces with the following cell-binding moieties peptides: RGDS, REDV, 
YIGSR, and their combinations to promote ECs adhesion and proliferation.  
The use of short synthetic peptides as coating molecules has emerged as a 
powerful approach to overcome limitations associated with the use of proteins. 
This work selected the use of RGDS, REDV, derived from human fibronectin, and 
YIGSR, present in laminin, and their combinations to enhance endothelialization.  
 
The use of combinations of peptides was the main contribution of this study.  
The purpose of the present study was to determine the best strategy to promote 
ECs adhesion and proliferation. Thus, different peptides where synthetized with 
different spacers and bioactive motifs and attached onto CoCr surfaces. An 
extensive characterization before and after functionalization was performed for all 
the conditions. 
The results presented in this study showed the potential of the use of equimolar 
combinations the selected cell adhesive peptides. Demonstrating that they are a 
promising approach to improve endothelialization and migration, as well as to 
reduce SMCs adhesion.   
  5 
1.3 Paper III (Chapter 5) 
Cell adhesive peptides functionalized on CoCr alloy stimulate 
endothelialization and prevent thrombosis and restenosis  
Authors: Castellanos MI, Guillem-Marti J, Mas-Moruno C, Díaz-Ricart M, Escolar 
G, Ginebra MP, Gil FJ, Pegueroles M, Manero JM.  
Manuscript published; J Biomed Mater Res A. 2017;105(4):973-983. 
(DOI: 10.1002/jbm.a.35988) 
IF: 3.263 (2015), Q1 ranked 14/33 in the category ¨Material Science, Metals and 
Alloys¨ 
Presented in 25th ESB European Conference, Madrid, Spain. September 2013.  
Author's contribution: Major part of planning and analysis. Performed all the 
experiments, the analysis of the study and wrote the paper. 
 
The manuscript describes the study of biomimetic surfaces modifications to 
improve endothelialization CoCr surfaces but focused in the prevention of 
thrombosis and restenosis. The present study continues the work started at Paper 
II by using the surface coatings that enhance endothelialization onto CoCr 
surfaces, focusing on RGDS, YIGSR peptides and combination.  
A key factor in stents biomaterials is the effect in thrombogenicity and restenosis 
were an over-proliferation of SMCs causes the narrowing of the artery. Thus, the 
use of coatings that overcome the mentioned problems is of special interest.  
 
The main purpose of this study was to study the effect of functionalized CoCr 
surfaces with RGD, YIGSR peptides and their combination on the ECs gene 
expression of genes relevant for adhesion, vascularization, anti-thrombogenic and 
pro-thrombogenic events using RT-qPCR technique. Moreover, thrombogenicity 
was evaluated through platelet adhesion and aggregation and restenosis through 
cell co-cultures of ECs/SMCs.  
 
This study demonstrated that CoCr surfaces functionalized with an equimolar 
combination of RGDS and YIGSR peptides showed a decrease of SMCs and 
platelet adhesion.  
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2 Chapter 2: Literature Review 
 
The narrowing of the artery is due to fat and lipid accumulation in the arterial wall 
and causes the decrease in blood flow and the common surgery to solve it is 
called coronary angioplasty which consists of a stent placement. It is performed by 
inserting a catheter through the artery (i.e. femoral, radial or brachial) to locate the 
artery to be treated. In 1964, the first angioplasty was described by Charles 
Theodore Dotter and Melvin P. Judkins [14]. Thirteen years later Andreas Grüntzig 
developed the first transluminal coronary angioplasty (CTA) with balloon [15]. 
From this first procedure, the intervention has evolved from the coronary bypass, 
which requires open heart surgery; to a balloon angioplasty, where the balloon is 
inflated until the obstruction is eliminated, culminating in percutaneous coronary 
interventions (PCI), commonly known as coronary angioplasty or simply 
angioplasty.  
Currently, the PCI [16], involve coronary stents using "simple balloon 
angioplasties" [17], giving a wide variety of stents, which are included in two large 
families: (i) BMS [7] to (ii) drug eluting stents (DES) [18] through a polymer coating 
on metal stent. The latter include different subfamilies depending on the type of 
drug they release (I.e. sirolimus eluting stent (SES), placitaxel-eluting stents (PES) 
everolimus eluting stents (EES), zotarolimus eluting stents (ZES), among others). As 
well as different types of polymer coatings, such as: phosphonilicoline (PC), 
heparin, [19], polyethylene terephthalate (PET) [20], n-butyl poly-methacrylate 
(PBMA), coatings with biodegradable polymers such as polylactic acid (PLA), poly-
acid-L-lactic acid (PLLA), poly-orthoester, poly-caprolactone and polyethylene / 
polybutylene terephthalate (PEO / PBTP) have been used. Finally, biodegradable 
stents (BDS) appeared recently and are under clinical studies; these are stent fully 
degradable in 12 to 14 months. At present, the third generation of stents attempts 
to use fully biodegradable and fully bio adhesive stents, whether polymeric (i.e. 
polylactic acid (PLA) or metallic (i.e., magnesium) [18].  
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Figure 2.1 Coronary Intervention timeline. Adapted from [1,21] 
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2.1 Vascular diseases 
 
Cardiovascular disease is one of the leading causes of mortality and morbidity in 
the world. According to the World Health Organization (WHO), 17.3 million 
people died from cardiovascular related diseases in 2008, and this number is 
projected to rise to an estimated 23.6 million by 2030 [22].   
 
Atherosclerosis [3] is one of the most severe forms of cardiovascular disease and  
artery injury, it causes the narrowing of the vessel wall. It is characterized by 
calcification and the buildup of fatty deposits, cellular fragments and cholesterol in 
arteries, resulting in stenosis of the vessels. If this occurs in coronary arteries, 
insufficient delivery of oxygenated blood to the heart would result in cardiac 
ischemia, ultimately leading to a heart attack.  
Blocked arteries can be treated either by a coronary artery bypass graft (CABG) 
surgery or, a less invasive technique, percutaneous angioplasty followed by stent 
placement, the PCI intervention. [23,24] 
Figure 2.2 Stages of atherosclerotic plaque establishment. Adapted from [25].     
 
Intracoronary stenting demonstrated feasibility of dilating atherosclerotic coronary 
lesions; however, the high rate of acute-vessel recoil, restenosis and dissection 
resulted in high acute closure rates and restenosis, which lead to the introduction 
of coronary stents, improving clinical outcome, the BMS. This type of stents 
reduces significantly the restenosis rate from 30-50% to 20-30% [6]; however, the 
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major issue with the use of BMS was the high incidence of ISR, which results 
mainly from the SMCs over proliferation and the ECM components production 
[26].  
 
The second generation of stents, DES, have reduced the restenosis rate to 10% by 
inhibiting the SMCs proliferation through the delivery of antiproliferative drugs. 
The development of this type of stents was divided into two generations; the first 
one (especially SES and PES) resulted in a dramatic reduction of restenosis, with a 
decrease in revascularization procedures.  However, the undoubted efficacy of 
first generation DES came at the expenses of substantially delayed arterial healing, 
proving the presence of late stent thrombosis / very late thrombosis (LST/VLST). 
Second-generation DES (EES and ZES) were designed to overcome the limitations 
of the first-generation DES and consisted of thinner stent struts, more 
biocompatible polymeric coatings with reductions in drug load. However, the new 
DES show delayed arterial healing associated with increased rates of ST and DES 
compared to BMS, due to the non-complete re-endothelialization. 
 
Finally, bioresorbable stents (BRS) were recently introduced in cardiology and 
represent a promising solution to overcome many of the limitations of metallic 
DES. However, most recent data suggest that BDS technology is also hampered 
by some important shortcomings that need to be solved by novel design of BDS 
and innovative coating technology mainly due to low mechanical properties related 
to the material [27].   
 
A timeline of the different generations of stents and their actions and side effects 
is shown in Figure 2.3. 
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Figure 2.3 Timeline of the different generation of stents consequences.  
 
2.2 Biomaterials for BMS  
 
The main objective of the BMS were to counter the negative effects of the 
balloon angioplasty, describing the stent as a metallic mesh, which should address 
properties such as: rigidity for maintenance the dilatation and resistance to the 
elastic recoil, elasticity or plasticity for expansion, corrosion, radiopacity and radial 
strength [7].   
Therefore, from the viewpoint of mechanical properties, it is natural that stents are 
made of metals.  The metallic materials most currently used for coronary stents are 
316L stainless steel, cobalt chromium (CoCr) alloys and titanium and its alloys [28–
30]    
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Table 2.1. Metals and properties needed for stents materials. Adapted from [31]. 
 
Stainless Steel  
Most stents consist of austenitic stainless steels 316L. The main reason for the 
use of stainless steels is the good balance of mechanical strength (Young’s 
modulus E ≈ 193 GPa) and elongation which facilitates the manufacture of the 
stent, the plasticity for the balloon expansion and the maintenance of morphology 
to resist the elastic recoil of blood vessels. Stainless steels do not corrode in an 
oxygen-containing atmosphere, but they show pitting and crevice corrosion when 
implanted in the body [7].  
 
Ni-Ti alloy (Nitinol)  
Nitinol alloys consist of equal atomic amounts of Ti and Ni (49-51 mol% Ni) and 
shows unique mechanical properties such as shape memory, super elasticity, and 
damping [29]. The main disadvantage of these alloys are the low resistance to 
pitting corrosion, as well as the release of Ni ions, which are toxic and in some 
patients present hypersensitivity, as well as the difficulty of manufacture [30]. 
 
 
CoCr alloys  
CoCr alloys show high strength, toughness, castability, corrosion resistance, and 
wear resistance. The corrosion resistance of CoCr alloys is better than that of 
stainless steel. The wear resistance is much better than those in stainless steel and 
Ti alloys, but the plasticity and workability are not as good as those of stainless 
Yield strength 
(MPa) 
Ultimate thesile 
strength (MPa) 
Young's 
modulus (GPa)
Max  
elogantion (%)
CoCr alloys: 
CoCrWNi (F90)
Co; 19-21Cr; 14-16 W; 
9-11 Ni 310 860 210 20
Stainless steel: 
316L type  
Fe; 16-18.5Cr; 10-
14Ni; 2-3Mo; <2Mn; 
<1Si; <0.003C
190 490 193 40
Ti alloys:              
Ti-6Al.4V alloy 
(F136)
Ti; 5.5-6.75Al; 3.5-
4.5V; 0.08C; 0.2O 795 860 116 10
Metals
Main alloying 
composition (wt%)
Mechanical propierties
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steel. The main CoCr alloy used for coronary stents fabrication is ASTMF90, which 
composition is exhibited in Table 2.2 
 
Co alloys are divided into two categories, cast alloys, and wrought alloys, that’s the 
reason for the Ni presence, improving the castability and workability of the 
material, although for biomedical application the Ni contents should be reduce in 
order to avoid the Ni allergies [29].  
 
Wrought CoCr alloys, which are used for stents, were designed to avoid cast 
defects in cast CoCr alloys. The strength and elongation of wrought CoCr alloys, 
which increase with heat treatment and cold working, are as high as those of 
stainless steel. The corrosion resistance of the wrought CoCr alloy is lower than 
that of the cast CoCr alloy, but higher than that of stainless steel [7]. 
 
Table 2.2. CoCr composition and properties. Adapted from ASTM F90 [32] 
 
Current stent technology 
The current stent technology is associated by deployment method, manufacture 
and production; geometry also plays an important role regarding the mechanical 
properties.  
% min max
C 0.05 0.15
Co Balance Balance
Cr 19.00 21.00
Fe -- 3.00
Mn 1.00 2.00
Ni 9.00 11.00
P -- 0.040
S -- 0.030
Si -- 0.40
W 14.00 16.00
Cold-work
760
15.030.0
Composition
Yield Strenght (MPA)
Annealed 
310
Elongation (%)
  13 
The first deployment method is balloon-expandable, the stent is deployed by 
expanding trough a balloon catheter, affecting the plastic deformation of the 
material, (i.e. 316L, CoCr alloys, Ta alloys etc.); or self-expanding (i.e. NiTi alloys).  
Stent manufacturing is distinguished by three physical forms: sheet, wire (round or 
flat) and tube; and finally the most common way of produce stents are: laser 
cutting, electrode discharge machining, waterjet-cutting and photochemical 
etching for tubing [6].  
There are three stents geometry types: (1) slotted tube which are produced using 
tubes of metal; (2) coil, which is made by metallic wires or strips forming a circular 
coil and; (3) tubular mesh which consist of wires wound forming a tube. Also, the 
stents differ slightly in strut pattern, width, length, diameter, metal composition, 
radiopacity.  
All the presented parameters influence deeply the results of thrombosis and 
restenosis rates [33,34].  
 
2.3 Biological mechanisms   
 
When a stent is placed in to the artery to overcome atherosclerosis and vessel 
occlusion, it is an inevitable consequence to have arterial injury. Due to PCI’s, a 
cascade of cellular and molecular events occurs resulting I acute disruption of the 
endothelial layer of the arterial wall. Atherosclerosis is mainly due to a disturbance 
of the normal endothelium; thus, understanding the biology of the vessel wall will 
be useful to understand the importance of having a functional endothelium for 
vascular health [35].  
  
2.3.1 Artery structure and healthy endothelium  
Native artery is an extremely complex multi-layered tissue composed of a number 
of different proteins and cell types, which each play an integral role in the 
mechanical behavior of the structure (Figure 2.4) It is composed of the following 
parts [36]:  
• Tunica intima, is the innermost layer of the vessel wall and it contains 
elastic and connective tissue connected with a monolayer of ECs in contact 
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with the deep internal cavity where the blood flows, also called the lumen. 
The ECs monolayer is called the endothelium which is in contact with 
circulating blood and, in healthy conditions, produces many molecules with 
antithrombotic properties, including nitric oxide, prostacyclin, tissue 
plasminogen activator, thrombomodulin, heparin-like molecules, and tissue 
factor pathway inhibitor [35]. Moreover, the endothelium permeability is 
also crucial to provide a barrier between the vessel lumen and surrounding 
tissue [37,38].  
 
 The most obvious function of the intimal or endothelium is to keep the 
 blood inside the vessels; At the same time, allows the exchange of nutrients 
 with the interior of the tunica media, another function is to control blood 
 coagulation, and inhibit coagulation. 
 
• Tunica media, is composed of elastic tissue and several layers of SMCs in a 
matrix of collagen types I and III, elastin and proteoglycans. SMCs are 
spindle-shaped cells; they can proliferate and migrate to the intimal in 
response to some growth factors (e.g. PDGF, FGF) produced by the ECs, 
being the cause of restenosis.  
 
• Tunica adventitia or tunica externa, is the most external layer composed of 
connective tissue with fibroblasts, microvascular networks and randomly 
arranged collagen type I [39,40]. Fibroblasts are the connective tissue 
reproductive cells, which synthesize collagen and glycosaminoglycan’s. 
They are important during the wound healing, as they migrate and 
proliferate. In fact, fibroblasts constitute the scar tissue after a heart attack.  
 
Each of these layers are separated by elastic fibers called the internal and external 
lamina. 	 
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Figure 2.4. Anatomy of an artery consisting in three primary layers: intima, media and adventitia. From  [41] 
 
A healthy endothelium is characterized by an optimal intercellular junctions and 
antithrombotic properties.  
The integrity of the endothelium is maintained by the intercellular junctions, which 
regulate its permeability and signal transduction, as well as in endothelial cell 
growth and survival. Intercellular junction and integrin receptors link the 
endothelial monolayer to the actin cytoskeleton in order to prevent separation of 
these cells from each other and the substrate [42].  
Thigh-junction components interact with several signal-transduction molecules, 
such as G proteins, protein kinases, and molecules that regulates cell growth and 
survival.  
The vascular endothelial cadherin, might transfer intercellular signals, which lead to 
inhibition of endothelial cell apoptosis, they also inhibit endothelial cell growth and 
motility by inhibiting vascular endothelial growth factor (VEGF) receptor 2, and 
activating the growth factor !	 (TGF- !), which has antiproliferative and 
antimigratory properties [36].  
The transmembrane protein platelet/endothelial cell adhesion molecule 1 
(PECAM-1) is constitutively expressed at the intercellular borders of the ECs, but 
has not a direct part in the junction complexes [35].   
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The antithrombotic properties of the endothelium are conferred trough the 
inhibition of platelet aggregation and blood coagulation, as well as by plasminogen 
activator. The endothelium produces nitric oxide (NO) through enzymatic 
conversion of L-arginine by endothelial nitric oxide (eNOS) [43], which activity is 
regulated by different substances. If platelet aggregation occurs in a healthy 
coronary artery, platelet-derived serotonin, ADP, and locally thrombin bind to their 
receptors on the endothelial surface; this bind leads to eNOS activation, and 
subsequently yield the NO production by the own endothelium, as well as the 
cyclic-GMP (cGMP)-mediated relaxation of SMCs resulting in increased blood flow 
and inhibition of the coagulation cascade. Meanwhile, ECs produce antithrombotic 
and prothrombotic molecules, blood coagulation and platelet aggregation are 
inhibited by NO; tissue-type plasminogen activator (tPA) [44] promotes fibrinolysis. 
Prothrombotic molecules generated by ECs include von Willebrand factos (vWF) 
[45] and plasminogen activator inhibitor (PAI-1), which promotes platelet 
aggregation, allowing the activation of thrombin, and triggering the initiation of the 
blood coagulation [46], See the wound healing process described above in Figure 
2.5.  
 
Figure 2.5. The wound healing in the artery. Adapted from [47] 
VCAM-1
ICAM-1
adhesion
vascularization
pro-thrombogenic
anti-thrombogenic
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2.3.2 Endothelial dysfunction  
Atherosclerosis is the main cause of disturbance of the normal endothelial 
function.  It is characterized by endothelial activation with pro-inflammatory and 
pro-coagulation environment and discontinue vasodilatation.   
Other cardiovascular risk factors such as hypercholesterolemia, diabetes mellitus, 
hypertension, and smoking, contribute to the development atherosclerosis and 
hence endothelial dysfunction [35].  
Restenosis  
Restenosis or the re-narrowing of the arteries [23], is a process that begins with 
the damage caused by the balloon in the arterial wall at the time of the PCI, which 
is the long-term evolution of atherosclerosis due to a slow growth of the 
atherosclerotic plaque leading to final obstruction of the artery and restricts blood 
flow and impedes the supply of oxygen and nutrients [6]. The presence of 
atherosclerotic plaque compromises the integrity of the lumen of coronary 
arteries.  
There are 4 mechanisms through which restenosis can be achieved: (i) Elastic 
retraction of the first day after implantation, (ii) Formation and organization of 
mural thrombus and inflammatory response, (iii) Neointimal proliferation and (iv) 
Chronic remodeling also known as geometric alterations [24,25]. Inflammatory 
cells exert a primary factor in vascular wall repair and neointimal formation, as well 
as the migration and proliferation of SMCs from the middle layer.  
 
Figure 2.6. Illustration of Restenosis disease due to angioplasty. Adapted from [34] 
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Thrombosis 
Thrombosis is a quick and acute complication corresponding to the rupture of the 
endothelium. The development of deep thrombosis is as follows: (i) Normal blood 
flow through the vein, (ii) Fibrin accumulation in the vein, (iii) thrombus formation 
with blood and platelets, (iv) Thrombus and occlusion of the blood flow and (v) 
Embolism or thrombus formation: thrombosis. [26–28] 
 
Figure 2.7. Determinants of thrombosis in coronary atherosclerotic plaques. Adapted from [23] 
 
2.3.3 Consequences of stents implantation  
Elastic recoil due to the contraction of the elastic fibers of the internal and 
external lamina, is another disturbance, creating an early phase of restenosis. Stent 
deployment disrupts the endothelium, crushes the plaque, triggering and over-
exposes collagen, FN, vWF and LN, allowing the platelets to aggregate and thus, 
the thrombus formation, creating a wall injury, that presents clot formation where 
the macrophages get attracted due to the metallic foreign surface.  Finally, it 
occurs an uncontrolled proliferation and migration of SMCs to the intima leading 
to the formation of ISR [6,47]. 
In-stent restenosis (ISR)  
ISR is the re-narrowing of arteries after insertion of a stent, it is dominated by 
neointimal growth, induced by SMCs over proliferation [4]. Patients treated with a 
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BMS have a rate of ISR around 15-20% and it is the most concern disease linked 
to BMS. The difference lies histologically from restenosis after balloon angioplasty 
and comprised largely of neointimal formation; suggesting that ISR virtually 
eliminates vessel elastic recoil and negative remodeling, subsequent in a large 
neointimal formation [48].  
 
 
Figure 2.8. Mechanism leading to in-stent restenosis, from [42]  
 
Stent thrombosis (ST)  
ST can occur by the delay of endothelium healing of angioplasty site and the 
exposure of the stent biomaterial. The factors associated with ST may be: the 
stent (geometry, material and drug); the patient including clinical history and 
conditions; the procedure and the extend and duration of antiplatelet therapy [49].  
 
2.4 Interactions between ECs and biomaterial surfaces  
 
Actual stent technology fails to completely reduce ISR and ST diseases. ECs 
adhesion on biomaterials surfaces is required to provide a non-thrombogenic 
surface, but also cell proliferation and migration. The ability of a material to 
support cell adhesion depends on its surface properties [50]. Treatments to 
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modify a surface chemistry or topography have been used to induce protein 
adsorption and cell adhesion.  
2.4.1 Stent physico-chemical modifications 
Studies have shown that a rough surface is more auspicious to increase the 
thrombogenicity [51,52], for that reason obtain a contamination-free and smooth 
surface is essential for stents applications. Mechanical polishing, ultrasonic cleaning 
and chemical etching are some of the solutions to acquire a smoother surface.  
Coatings have been used to primarily enhance stent biocompatibility but they have 
also become a platform for the controlled delivery of drugs. Stents coatings can be 
generally classified as passive and active coatings. 
 
a) Passive coatings  
This type of coatings act only as an inert barrier between the 
bloodstream/endothelium and metal, with the objective to increase the 
biocompatibility of the material, as well as to reduce neointimal hyperplasia, 
obtaining a surface with low thrombogenicity.  
Passive coatings are divided into inorganic and organic compounds [53,54] to 
create a superficial layer or inorganic material, allowing a faster cleaning of the 
surface, remove the extra-material from the surface, decrease the percentage or 
carbon and nitrogen and increased the amount of hydroxyl groups, and oxygen in 
the surfaces. This simple procedure: Activation is an interfacial bonding layer, in 
order to create a reactive surface for the subsequent immobilization of the active 
molecules, and increase the oxide layer and improve the corrosion. The drawback 
in Plasma activation is that the effect of clean surface, is very low and this is 
related to the weak bond created with the metal and low surface density of 
carboxyl groups [55].  
NaOH etching, a treatment that generates accessible hydroxyl groups on the 
surfaces, which is also considered as an inorganic coating and used as an 
activation technique, which occasioned a slightly increased in the nano-roughness 
of the surfaces, case that not happen in Plasma, also NaOH increased the amount 
of oxygen and nitrogen while slightly decrease carbon content, due to the lower 
removal of carbonaceous species.  
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NaOH etching was inspired from Kokubo [56] method, used over Ti surfaces, to 
generate a stable layer over the surface, increasing the roughness and wettability, 
characteristics wanted over our surfaces.  
Inorganic stent coatings usually are chemically stable and serve as hemocompatible 
coatings and corrosion inhibitors. The most commonly used inorganic coating 
materials for stents are gold (Au), chromium (Cr), titanium (Ti) platinum (Pt) and 
cupper (Cu). Also, silicon carbide (SiC) or metal oxides are used.  
Organic polymer allows a higher accessibility to chemical surface modification 
compared to inorganic coatings. Biostable coatings generally have good 
mechanical and biocompatible properties i.e. polyethylene terephthalate (PETP), 
Polytetrafluoroethylene (entree), Poly ethyl methacrylate (PMMA), but, in some 
cases, problems of inflammation and increased neointimal formation have been 
detected.  Biodegradable polymers can be mechanically stable and 
hemocompatible. i.e. Polyglycolide (PGA), Polylactic acid (PLA), L-polylactic acid 
PLLA, Polycaprolactone (PCL) biocompatible (i.e. Hyaluronic acid, fibrin and 
heparin) [6].  
 
b) Active coatings 
Are usually defined as those that stimulate a certain cellular response, this can be a 
biomolecule directly bond to the surface of the stent, or a polymer that acting as a 
reservoir. The best example of this types of coating are the DES stents, which 
release higher concentrations of a locally drug into de blood to reduce restenosis 
rates. 
 
2.5 Surface chemical functionalization  
 
Surface attachment of bioactive molecules such as ECM proteins, adhesive 
peptide sequences and/or growth factors have been used to promote EC 
adhesion onto materials and to control cell processes such as proliferation, 
migration, differentiation and survival.  
Several approaches have been explored to improve vascular healing after stent 
implantation and, in particular re-endothelialization of stent struts [57,58], from 
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coating with complex full-length proteins [59], biopolymers [60,61], to biologically 
relevant peptide sequences [10,62,63]. In order to improve biofunctionality, 
affinity and selectivity of the ligand; multiple peptide motifs, peptide mixtures, 
branched and cyclic peptides, and engineered protein fragments have been 
designed to increase the efficacy of functionalization. Table 2.3 summarizes all the 
studies related to the use of bioactive molecules to promote ECs processes. 
 
2.5.1 Cell recognition motifs 
2.5.1.1 Protein coatings  
Surface treatment may enhance cell adhesion by modifying protein adsorption but 
the exact composition of the adsorbed layer is not known and cannot be 
controlled or reproduced. The use of components of the ECM such as cell 
adhesive proteins like fibronectin (FN) [64,65], collagen [66] or laminin [67], have 
facilitated cell attachment onto biomaterials and promote their biocompatibility. 
Although the proteins used brings some disadvantages [68,69]:  
• Proteins are obtained from other organisms and purified, creating an 
undesirable immune response and increase of infection risks.  
• Proteins are enzymatically unstable and present degradation, formulating a 
long-term impossible to produce.  
• Only one part of the proteins is able to orientate and support cell adhesion.  
• The functionalization of protein coated surfaces is difficult to control, since 
the physical-chemical properties such as charge, wettability and 
topography, conformation and the proteins orientation can influence 
protein deposition onto the material and, thus, biomaterials cell response 
[69]. 
Most of the drawbacks presented, could be solve using small part of the full-length 
protein.  
2.5.1.2 Grafting synthetized peptides 
Since the discovery of amino acid sequences within ECM proteins specifically 
recognized by cell receptors, many researchers have immobilized cell recognition 
peptides directly onto materials surfaces in order to control cell behavior [69]. The 
advantages of grafting short synthetic peptides onto biomaterials are: 
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• They provide binding specificity. 
• They exhibit higher stability, especially in sterilization conditions and heat 
treatment.  
• They are easy to synthetize and control, which makes that have a better 
cost-efficiently results.  
Surfaces modified with bioactive cell-adhesive peptides have shown to mediate 
anchorage-dependent cell functions, including adhesion, proliferation and 
migration.  
 
• RGD  
RGD represents by far the most extensively studied cell adhesion motif used to 
functionalize surfaces. It is  present in FN and has been identified as a minimal 
essential cell adhesion present in this protein [70], and is the most effective 
sequence to stimulated cell adhesion [69], due to its ability to address more 
than one cell adhesion receptor and its biological impact. This peptide 
sequence has been also identified in other ECM proteins, including vitronectin, 
fibrinogen, vWF, collagen, laminin [71].  Eight receptor subtypes integrins have 
been demonstrated to recognize and bind with RGD peptide: αvβ1, αvβ3, 
αvβ5, αvβ6, αvβ8, α5β1, α8β1 and αIIbβ3 [72,73].  
ECs are known to express β1 integrins, which made the possibility to promote 
the ECs and re-endothelialization through this short-peptide, although being a 
non-specific sequence, presents SMCs and platelet adhesion.  
 
• REDV 
 REDV sequence has been found in FN and it mediates EC migration on FN via its 
α4β1 receptor [74,75]. Moreover, it has been reported to selectively promote EC 
adhesion and spreading over SMCs and platelets [76,77], 
 
• YIGSR  
The laminin derived YIGSR sequence [78] have been shown to promote ECs 
adhesion and migration without enhancing platelet adhesion [79]. A wide variety 
of cell types has been reported to express immunologically related laminin-binding 
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proteins within this size range, including SMCs, macrophages, neutrophils, 
epithelial cells and endothelial cells.  
 
2.5.1.3 ELRs 
ELRs are oligomeric macromolecules based on the repetition of the (VPGXG) motif 
from elastin, in which X is any amino acid except L-proline [80]. The composition is 
strictly defined by engineering design and enable the introduction of peptide 
sequences to extend their properties, they are produced as recombinant proteins 
mimicking the basic properties of elastin and exhibiting mono-dispersity and a high 
control over amino acid sequence [81,82]. The recombinant nature of ELRs allows 
to include bioactive domains such as endothelial cell attachment sequence REDV 
[10,81],  
The basic structure of ELRs is a repeating sequence, that has his origin in the 
repeating sequences found in the mammalian elastic protein: Elastin [83].  
 
2.5.2 Binding of ligands  
Synthetic peptides are usually firmly linked to the surfaces either directly or via a 
spacer to enhance their steric availability and conformational freedom, thus 
promoting their binding. There are two major strategies to biofunctionalized 
biomaterial surfaces: physisorption and covalent grafting or silanization.   
 
2.5.2.1 Physisorption  
This process, relies in the non-covalent interaction between the biomolecule and 
the surface, consists of an immersion of the sample into a bioactive peptide 
containing solution, counting only in the electrostatic forces, hydrophobic 
interactions, hydrogen and van der Wall forces bonds, this is the simplest way to 
create the bonding, although is a weak interaction due to there is a lack of 
controlled deposition and the stability of the peptide over the surface could be not 
guaranteed. Therefore, the success of the adsorption is based on the physico-
chemical properties of the biomolecule and the surface properties.  
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2.5.2.2 Covalent grafting 
On the other hand, silanization has been widely used to covalently immobilize 
functional biomolecules on metallic supports [28,58] which brings and alternative 
to the lack of stability present in the physisorption, due to the chemical 
functionalities of the material surface to covalently bind the bioactive molecule.  
 
3-chloropropyltriethoxysilane (CPTES) silane was use to react with the exposed 
hydroxyl groups previously generated by the activation steps (Oxygen plasma or 
NaOH), allowing the binding of the silanes on the CoCr surfaces. [84,85]. Still, the 
successful and reproducible monolayer formation depends on the silane used, 
temperature and the techniques employed, in the case of metals, silanization is 
limited by the low surface hydroxyl group content of the native oxide layer, this 
problem can be overcome, by adding of activation treatment before mentioned. 
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Table 2.3 Summary of potential peptides or other moieties intended to enhance vascular graft endothelialization through biofunctionalization 
Molecule 
(peptide) 
Surface  
(Application / surface 
modification) 
Cell type model Outcome  Ref 
ELRs (RGD and 
REDV) 
Bare metal stents HUVECs In vitro 
Shows an effective generation of covered stents which exclude 
the atherosclerotic plaque from the blood stream and have high 
biocompatibility. 
[86] 
2015 
Oligonucleotides 
(ONs)  
CoCr stents  EPCs In vitro 
Stents were successfully functionalized with the specific ON, 
increasing cell adhesion.  
[87] 
2015 
Albumin and 
Fibrinogen  
CoCr alloy with PA and PAA Platelet adhesion In vitro  
Demonstrated that PA coating on CoCr alloy was superior to 
PAA coating for reducing platelet adhesion, activation, and 
aggregation.  
[88] 
2015 
Placitaxel (PAT)   CoCr alloy ECs and SMCs In vitro  
This study showed the interaction of ECs and SMCs with SAMs-
CoCr and PAT-SAMs-CoCr, being the first one better for 
endothelialization. 
[89] 
2013 
Heparin and FN  Ti ECs In vitro 
The Hep/FN co-immobilization improve the blood compatibility 
and promotes endothelialization 
[59] 
2011 
Anti-CD34 with 
Multilayer of 
Heparin/collagen 
Si, PET, 316 stainless steel  ECs and SMCs 
In vitro and in 
vivo (rabbit) 
The functionalized multilayer heparin /collage + antiCD34 show 
selectivity to promote the ECs. 
[90] 
2010 
P15 peptide ePTFE 
HUVECs and 
HUASMCs 
In vivo (sheep 
model)  
The EC adhesion, proliferation has increased, while the controls 
presented a thicker neointimal hyperplasia.  
[91] 
2012 
RGD PCL - scaffolds 
ECs, SMCs and 
Platelet adhesion 
In vivo (rabbits) RGD-modified PCL grafts exhibit an improved remodeling and 
integration capability in revascularization 
[57] 
2012 
RGD 
PLL-g-PEG / PEG-peptide, 
covalent conjugation  
Fibroblasts In vitro 
Creation of specific signal for cells and inhibited non-specific 
adhesion 
[92] 
2003 
+RGDS 
NiTi with Self-assembly 
peptide PA nanofiber 
Covalent attach APTES 
Pre- osteoblasts 
MC3t3-E1 and 
CPAE 
In vitro 
Covalently attach self-assembled PA nanofibers on pre-treated 
NiTi substrates using an intermediary amino-silane layer. 
[93] 
2008 
RGD ePTFE AHSHVECs In vitro  
Low concentrations of RGD peptide cross-linked led to 
significantly increased endothelial cell retention. 
[94] 
2005 
  27 
RGD cyclic Guidant Tetra Stents  Porcine EPC 
In vivo / porcine 
model 
The data indicate a crucial role of !v"3	integrins, improving the 
endothelialization and therefor decreasing the neointimal 
stenosis 
[95] 
2006 
REDV 
PEGMA and Glycidyl 
methacrylate (GMA)  
ECs and SMCs In vitro  
The copolymers GMA and PEG groups are very useful as a 
multifunctional coating material with anti-fouling and ECs 
specific adhesion for implant materials surface modification 
[96] 
2015 
REDV SiO2 substrates ECs and SMCs In vitro  
The covalently bound peptide reduced apoptosis and necrosis 
of adhered cells, meanwhile both short peptides were superior 
to FN in increasing adhesion 
[77] 
2006 
REDV PU  HUVECs In vitro  
Shows a positive effect of REDV peptide after surface 
modification over HUVEC 
[97] 
2016 
REDV 
Zwitterionic carboxybetaine 
methacrylate and butyl 
methacrylate  
HUVECs 
HUASMCs, 
platelet adhesion 
and co-culture 
In vitro  
The coating was able to enhance the competitive growth of 
endothelial cells while limiting the adhesion, proliferation, and 
migration of smooth muscle cells 
[98] 
2012 
REDV 
Polysaccharide multilayer 
(PEM) 
HUVECs and 
HUASMCs 
In vitro  
REDV functionalized cell-resistant heparin/chitosan multilayer is 
a ECs selective surface 
[99] 
2012 
REDV 
Poly (ethylene glycol) 
methacrylate (PEGMA), PET 
and PDMS 
HUVECs and 
HASMCs 
Cell migration 
and in vivo. 
Demonstrated the competitive ability of EC over SMCs, and 
that the synergic action of the REDV could increase the 
selectivity 
[10] 
2013 
REDV 
PEG through   active $-
nitrophenyloxycarbonyl 
group 
HUVECs and 
HASMCs, cell 
co-culture 
In vitro 
The combination of nonspecific resistance of PEG and the ECs 
selectivity of REDV peptide presents better ability to enhance 
the competitive adhesion of HUVECs over HASMCs 
[100] 
2011 
YIGSR Polyurethaneurea with PEG HUVECs In vitro 
There is not existent of platelet adhesion, while EC adhesion, 
spreading and migration exist. This material is interesting for a 
small diameter vascular grafts 
[79] 
2005 
GRGDS and YIGSR 
Polyurethane (PU) with PEG 
spacer. 
ECs In vitro 
Surface co-immobilization was successfully created, allowing to 
create an EC-specific vascular graft with long-term patency 
[101] 
2013 
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RGD and YIGSR 
Polydopamine (pDA) 
coatings 
EPCs 
In vitro and In 
vivo  
pDA-mediated peptide immobilization enhanced adhesion, 
metabolic activity, and endothelial differentiation of hEPCs. 
[102] 
2014 
RGD and YIGSR PET and PTFE HUVEC’s In vitro 
Demonstrated that covalently immobilized adhesion peptides 
promoted attachment and spreading of HUVECs 
[103]  
1991 
RGDS and YIGSRG Borosilicate glass ECs 
Cell adhesion 
and migration 
The immobilization of the cell adhesive peptides increased the 
movement in the cells, leading to enhanced endothelialization 
rates 
[104] 
2000 
YIGSR and VAPG Amphiphiles peptide (PAs) 
HUVECs and 
AoSMCs 
In vitro 
Improve in the develop of novel vascular grafts, that mimic the 
native endothelium 
[105] 
2010 
RGD and REDV Gold-coated polyurethanes  HUVEC In vitro  
The gold-coated have significant potential especially the 
CCRRGDWLC peptide 
[106] 
2001 
RGD and QPPRARI PTFE  HUVECs In vitro 
Results demonstrated the increment of HUVEC adhesion, 
spreading and migration  
[107] 
2005 
RGD, REDV, YIGSR  dPVCs, OP and cBPI) EC 
In vitro and in 
vivo 
dECM was successfully functionalized with custom made 
synthetic peptides showing increased EC attachment on 
functionalized dPVCs 
[108]  
2016 
RGD, REDV and 
YIGSR 
PEG/ PET 
HUVECs and 
HVSMCs 
In vitro 
Demonstrated that cell-binding ligands immobilized RGD, YIGSR 
and REDV show normal monolayers 
[76] 
1991 
RGD, REDV and 
YIGSR 
Polysaccharide hybrid 
hydrogel (ALG-peptide) 
HUVECs 
In vitro and in 
vivo and blood 
vessel formation 
GREDV exhibited a superior capability for promoting the 
proliferation and selective adhesion of HUVEC over RGD and 
YIGSR. Stimulating new vessel formation 
[109] 
2015 
RGDS, REDV, 
YIGSR and 
SVVYGLR 
Polyethylene terephthalate 
(PET) 
HUVECs In vitro 
The combination of peptides specific for ECs RGDS and 
angiogenic sequence helps to improve endothelialization and 
vascularized tissue 
[110] 
2012 
RGD, YIGSR and 
IKVAV 
PCL 
Adipose-derived 
stem cells (ASCs)  
In vitro 
The results show that IKVAV-treated surfaces had a significantly 
greater number of ASCs 
[111] 
2006 
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  VII 
6 General discussion   
 
 
The use of stents has represented a revolutionary advance in the treatment of 
cardiovascular disease; but ISR and ST remain the major limitations of coronary 
intervention. To overcome these drawbacks and obtain a functional artery after 
coronary stent implantation, it is decisive to accelerate stent surface 
endothelialization [10,11]  and, if possible, without the use of antiproliferative 
drugs that generally delay the formation of healthy endothelium [8].  
 
One of the most promising strategies to improve implantable devices is the 
immobilization of cell adhesive molecules onto the surface, also called 
biofunctionalization. The aim of this thesis was to enhance endothelialization of 
CoCr alloy surfaces by functionalization for coronary implants. Different 
approaches were applied to functionalize the CoCr surfaces and, thoroughly, 
physico-chemically characterized and biologically evaluated in vitro with ECs, 
SMCs, co-culture of ECs/SMCs and platelets. This chapter highlights and discusses 
the main achievements obtained in this research. 
 
6.1 Biofunctionalization of CoCr surfaces with ELR 
 
Chapter III (Paper I) was focused on the immobilization of ELR, genetically 
modified with an REDV sequence, to enhance metal surfaces endothelialization. 
Different activation protocols (i.e. NaOH etching and O2 plasma) were applied to 
CoCr alloy surfaces to obtain a higher density of available hydroxyls and optimize 
the silanization process with CPTES. Both activation treatments increased the 
percentage of hydroxyl groups and thus, enhanced silanization and, finally, 
improved ELR immobilization. NaOH activated and silanized CoCr surfaces 
presented a major HUVEC adhesion and spreading due to a higher amount of 
immobilized ELR with REDV sequence. The reason for such increase was mainly 
attributed to a higher electronegativity of the surface, determined by zeta-
  VIII 
potential measurements, since roughness and wettability changes of NaOH 
activated surfaces were slightly different to plain surfaces. On the contrary, O2 
plasma activated surfaces were more efficient in generating hydroxyls onto the 
surface and changed surface wettability and chemistry by reducing the content of 
C and N. But the immobilized ELR was lower and thus, the number of adhered 
HUVEC decreased compared to NaOH activated surfaces.  
 
Differences between immobilization of ELR by physisorption and covalent binding 
were also detected by x-ray photoelectron spectroscopy (XPS), atomic force 
microscopy (AFM), fluorescent microscopy and quartz-crystal microbalance with 
monitoring dissipation (QCM-D). Covalent bonding coatings of the ELR onto CoCr 
alloy surfaces showed a higher amount and stability than the physisorbed ELR 
coatings, but this effect was not statistically significant. Probably, the silanization 
process was not optimal to obtain all the biomolecules covalently attached onto 
CoCr alloy treated surfaces and a mixture of covalent and physisorption behavior 
is obtained. The use of big biomolecules with different anchor groups causes the 
mixture of covalent and weak bonding between the biomolecule and the surface.  
 
6.2 Biofunctionalization of CoCr alloy surfaces with short synthetic peptides 
 
The control of the bonding between the biomaterial surface and the cell adhesive 
molecule has been reached with the design and synthesis of short synthetic 
adhesive peptides explored in Chapter IV (Paper II). 
Three main factors were considered for the biomolecules design: (i) the bioactive 
cell-binding motif, which determines the biofunctionality (ii) the anchoring group, 
which provides a strong and chemo-selective binding with the material, and (iii) the 
spacer, which ensures an optimal presentation and accessibility of the biomolecule 
to the cells. The final biomolecules design considered a thiol as the anchoring 
group and three amino-hexanoic acid (Ahx3) as best spacer to support EC 
adhesion for RGDS, REDV and YIGSR cell-binding motifs.  
Functionalization was performed onto CoCr alloy surfaces through physisorption 
and covalent binding using CPTES as coupling agent. To facilitate silanization, 
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surfaces were activated with NaOH to enhance silane coupling and, finally, the 
covalent binding of the peptides were performed in a buffer solution at basic pH 
to enhance the direct nucleophilic substitution between the free thiol group of the 
peptides and the organosilanes. The immobilization process of the cell adhesive 
proteins onto CoCr surfaces was successfully achieved for both routes. Moreover, 
equimolar combinations of the synthetized peptides were used to functionalize the 
surfaces. Biofunctionalized surfaces clearly increased the number, spreading and 
migration of adhered ECs independently of the type of immobilized peptide. 
However significant differences were detected depending on the peptide and 
immobilization strategy. It was particularly effective the silanization of CoCr 
surfaces with the equimolar combination of RGDS and YIGSR to enhance ECs 
adhesion.   
 
In addition to cell adhesion onto modified CoCr surfaces, the cellular crosstalk 
through ECs molecules is also a critical parameter for endothelial functionality. 
Chapter V (Paper III) evaluated the relevant genes for adhesion (ICAM-1 and 
VCAM-1) and vascularization (VEGFA, VEGFR-1 and VEGFR-2) which confirmed 
the beneficial effect of functionalization to increase ECs adhesion and activation.   
The expression of anti-thrombogenic factors (tPA and eNOS) increased over time 
for YIGSR coated surfaces. The fact that studied pro-thrombogenic genes (PAI-1 
and vWF) expression decreases over time, indicate that functionalization with the 
laminin-derived biomolecule could prevent thrombogenicity. Moreover, potential 
anti-thrombogenicity of peptides was also evaluated through platelet adhesion and 
aggregation by circulating human blood onto tissue cultures polystyrene (TCPS) 
coated with the studied biomolecules. All short peptides reduced platelet response 
compared to TCPS. 
 
A key point of the work is the influence of the different coatings to SMCs and 
platelet in vitro response treated in Chapter IV (Paper II) and Chapter V (Paper III). 
Immobilization of cell adhesive molecules increases SMCs adhesion although the 
values were ten times lower than those of ECs. The competition between both 
types of cells for the modified surfaces was evaluated in co-culture. As for single 
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cell in vitro studies, the results suggested a positive effect of functionalized 
surfaces to enhance ECs. The surfaces coated with the equimolar combination of 
RGDS and YIGSR exhibited adhesion selectivity towards ECs. Thus, a synergistic 
effect was observed between both molecules probably due to the fact that both 
peptides interact with different cell receptor molecules.  
 
Taking all together, the equimolar combination of RGDS and YIGSR seems to be 
the most promising strategy for endothelialization of CoCr alloy surfaces. Overall, 
functionalization of CoCr metallic surfaces for cardiovascular applications may 
offer an efficient alternative to enhance rapid endothelialization, while controlling 
restenosis and thrombosis.  
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7 Conclusions  
 
 
The present PhD dissertation has been devoted to enhance endothelialization of 
CoCr alloy surfaces for coronary implants. The following objectives have been 
achieved: (i) design and synthesis of short peptides with different spacers and 
active domains and using a thiol as anchor; (ii) development and optimization of 
the strategy of functionalization of CoCr alloy surfaces by covalently anchoring 
cell adhesive biomolecules; (iii) the study of the endothelialization capacity of the 
different treated surfaces by ECs adhesion, proliferation and migration in vitro 
assays; (iv) the study of the restenosis capacity of the different treated surfaces by 
SMCs adhesion and ECs/SMCs co-culture in vitro cell experiments.  
 
From the results of the three published papers, the following concluding remarks 
can be deduced:  
 
• The immobilization of elastin-like recombinamers onto CoCr alloy surfaces was 
successfully achieved by physisorption or covalent bonding by CPTES 
organosilane chemistry. ECs adhesion response was directly related to the 
amount of immobilized ELR onto the surface. Covalent bonding coatings of 
ELR showed a higher amount and stability than the physisorbed ELR coatings. 
Nevertheless, the silanization process was not completely effective since the 
use of big biomolecules with different anchor groups causes a mixture of 
covalent and weak bonding. Thus, both immobilization process and surface 
electrostatic forces influence the amount of immobilized ELR onto CoCr alloy 
surfaces.  
 
• The design and synthesis of short linear peptides (RGDS, REDV and YIGSR) 
were developed as biomolecules to be immobilized onto CoCr alloy surfaces by 
physisorption and CPTES silane covalent bonding. The appropriate anchor 
group, a thiol, and spacer, three units of aminohexanoic acid, were determined 
to obtain a chemo selective binding of the molecules to the biomaterial 
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surface. Moreover, the equimolar combination of RGDS/REDV and 
RGDS/YIGSR were also studied. The functionalized surfaces showed a 
significant increase of ECs adhesion and migration, particularly, the 
RGDS/YIGSR combination demonstrating the capacity of functionalization 
strategy to enhance endothelialization.   
 
• Surfaces functionalized with the linear peptides sequences RGDS, YIGSR and 
the combination RGDS/YIGSR showed a positive effect to enhance ECs 
adhesion also in co-culture with SMCs. The gene expression of anti-
thrombogenic factors tPA and eNOS increased over time of ECs cultured onto 
RGDS/YIGSR functionalized surfaces. Platelet adhesion and aggregation was 
lower onto YIGSR and RGDS/YIGSR coated TCPS surfaces compared to non-
coated after circulating human blood. Thus, RGDS/YIGSR functionalized CoCr 
surfaces is an efficient alternative to enhance rapid endothelialization, while 
preventing restenosis and thrombosis.  
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